These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26122079)

  • 1. Preclinical Development of New Therapy for Glycogen Storage Diseases.
    Sun B; Brooks ED; Koeberl DD
    Curr Gene Ther; 2015; 15(4):338-47. PubMed ID: 26122079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for glycogen storage diseases.
    Kishnani PS; Sun B; Koeberl DD
    Hum Mol Genet; 2019 Oct; 28(R1):R31-R41. PubMed ID: 31227835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for glycogen storage diseases.
    Koeberl DD; Koch RL; Lim JA; Brooks ED; Arnson BD; Sun B; Kishnani PS
    J Inherit Metab Dis; 2024 Jan; 47(1):93-118. PubMed ID: 37421310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.
    Koeberl DD
    J Inherit Metab Dis; 2012 Jul; 35(4):671-8. PubMed ID: 22310927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
    Jauze L; Monteillet L; Mithieux G; Rajas F; Ronzitti G
    Hum Gene Ther; 2019 Oct; 30(10):1263-1273. PubMed ID: 31319709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen storage disease types I and II: treatment updates.
    Koeberl DD; Kishnani PS; Chen YT
    J Inherit Metab Dis; 2007 Apr; 30(2):159-64. PubMed ID: 17308886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
    Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
    Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen storage diseases.
    Hannah WB; Derks TGJ; Drumm ML; Grünert SC; Kishnani PS; Vissing J
    Nat Rev Dis Primers; 2023 Sep; 9(1):46. PubMed ID: 37679331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large animal models and new therapies for glycogen storage disease.
    Brooks ED; Koeberl DD
    J Inherit Metab Dis; 2015 May; 38(3):505-9. PubMed ID: 25224826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.
    Han SO; Li S; Everitt JI; Koeberl DD
    Hum Gene Ther; 2019 Jul; 30(7):855-864. PubMed ID: 30803275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
    Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
    Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
    Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
    Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
    Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
    Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
    Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
    Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
    Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
    Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant AAV-directed gene therapy for type I glycogen storage diseases.
    Chou JY; Mansfield BC
    Expert Opin Biol Ther; 2011 Aug; 11(8):1011-24. PubMed ID: 21504389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.